74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
ADMA Biologics Inc
Closed
SectorHealthcare
19.4 -4.1
Overview
Share price change
24h
Min
19.16
Max
20.22
Income | 76M 112M |
|---|---|
Sales | -2.3M 118M |
P/E Sector Avg | 23.975 63.778 |
EPS | 0.136 |
Profit margin | 95.191 |
Employees | 685 |
EBITDA | -2.7M 40M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +28.73% upside |
Next Earnings | 8 May 2025 |
|---|
Market Cap | 797M 4.6B |
|---|---|
Previous open | 23.5 |
Previous close | 19.4 |
News Sentiment
By Acuity
50%
50%
180 / 386 Healthcare
Technical Score
By Trading Central
Confidence
Bearish Evidence
ADMA Biologics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
ADMA Biologics Inc Forecast
Price Target
By TipRanks
28.73% upside
12 Months Forecast
Average 25 USD 28.73%
High 25 USD
Low 25 USD
Based on 2 Wall Street analysts offering 12 month price targets forADMA Biologics Inc - Dist in the last 3 months.
Sentiment
By Acuity
180 / 386 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About ADMA Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
